{"id":"https://openalex.org/W1903592258","doi":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","title":"Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine","display_name":"Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine","publication_year":2010,"publication_date":"2010-08-24","ids":{"openalex":"https://openalex.org/W1903592258","doi":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","mag":"1903592258","pmid":"https://pubmed.ncbi.nlm.nih.gov/21545624"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2710.2010.01197.x","doi":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2710.2010.01197.x","source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2710.2010.01197.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108579793","display_name":"C. De Dios","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"C. De Dios","raw_affiliation_strings":["Department of Psychiatry, Hospital Universitario La Paz, Madrid, Spain. cdios.scsm@salud.madrid.org","Department of Psychiatry, Hospital Universitario La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Hospital Universitario La Paz, Madrid, Spain. cdios.scsm@salud.madrid.org","institution_ids":["https://openalex.org/I2800562746"]},{"raw_affiliation_string":"Department of Psychiatry, Hospital Universitario La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030621386","display_name":"Salvador Fudio","orcid":"https://orcid.org/0000-0001-7320-6139","observed_orcids":["https://orcid.org/0000-0001-7320-6139"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"S. Fudio","raw_affiliation_strings":["Department of Clinical Pharmacology, Hospital Universitario La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, Hospital Universitario La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057143023","display_name":"A. Garc\u00eda de Lorenzo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"A. Lorenzo","raw_affiliation_strings":["Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain","Dept of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]},{"raw_affiliation_string":"Dept of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2800562746"],"apc_list":{"value":2700,"currency":"USD","value_usd":2700},"apc_paid":null,"fwci":0.7674,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.71316046,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"36","issue":"3","first_page":"430","last_page":"432"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.961899995803833,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.961899995803833,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.007699999958276749,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0071000000461936,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valproic-acid","display_name":"valproic acid","score":0.9570000171661377},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8349999785423279},{"id":"https://openalex.org/keywords/parkinsonism","display_name":"parkinsonism","score":0.859000027179718},{"id":"https://openalex.org/keywords/cognitive-decline","display_name":"cognitive decline","score":0.9900000095367432},{"id":"https://openalex.org/keywords/bipolar-disorder","display_name":"bipolar disorder","score":0.9649999737739563},{"id":"https://openalex.org/keywords/manic-episodes","display_name":"manic episodes","score":0.6909999847412109},{"id":"https://openalex.org/keywords/cyp3a4-inhibition","display_name":"CYP3A4 inhibition","score":0.9509999752044678},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.9120000004768372},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.7549999952316284},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6269999742507935}],"concepts":[{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.88831627368927},{"id":"https://openalex.org/C2777172819","wikidata":"https://www.wikidata.org/wiki/Q240642","display_name":"Valproic Acid","level":3,"score":0.7363982200622559},{"id":"https://openalex.org/C2776525014","wikidata":"https://www.wikidata.org/wiki/Q1531991","display_name":"Parkinsonism","level":3,"score":0.7291831970214844},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6759628653526306},{"id":"https://openalex.org/C2911140283","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine Fumarate","level":5,"score":0.6431211233139038},{"id":"https://openalex.org/C2776174506","wikidata":"https://www.wikidata.org/wiki/Q131755","display_name":"Bipolar disorder","level":3,"score":0.5857140421867371},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.517287015914917},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.511482834815979},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4699081778526306},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4052586555480957},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.39918020367622375},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3610001802444458},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2865128517150879},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.2698497176170349},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.23310571908950806},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.22379407286643982},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.19039052724838257},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.13780301809310913}],"mesh":[{"descriptor_ui":"D000069348","descriptor_name":"Quetiapine Fumarate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001714","descriptor_name":"Bipolar Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D003987","descriptor_name":"Dibenzothiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003987","descriptor_name":"Dibenzothiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010302","descriptor_name":"Parkinson Disease, Secondary","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018692","descriptor_name":"Antimanic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018692","descriptor_name":"Antimanic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2710.2010.01197.x","doi":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2710.2010.01197.x","source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},{"id":"pmid:21545624","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21545624","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacy and therapeutics","raw_type":"Case Reports"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2710.2010.01197.x","doi":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2010.01197.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2710.2010.01197.x","source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1903592258.pdf","grobid_xml":"https://content.openalex.org/works/W1903592258.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1917748415","https://openalex.org/W1977879583","https://openalex.org/W1990182170","https://openalex.org/W1993517638","https://openalex.org/W2000503228","https://openalex.org/W2002993605","https://openalex.org/W2033342358","https://openalex.org/W2098103907","https://openalex.org/W2105015425","https://openalex.org/W2136777136","https://openalex.org/W2269314342","https://openalex.org/W2410676106"],"related_works":["https://openalex.org/W1530629220","https://openalex.org/W2080381507","https://openalex.org/W3085055041","https://openalex.org/W2595648687","https://openalex.org/W2129758368","https://openalex.org/W2185471291","https://openalex.org/W4393343643","https://openalex.org/W2079547615","https://openalex.org/W7203462085","https://openalex.org/W1990182170"],"abstract_inverted_index":{"WHAT":[0,76],"IS":[1,77],"KNOWN":[2],"AND":[3,79],"OBJECTIVE:":[4],"Combination":[5],"therapy":[6],"with":[7,29,37,49],"valproic":[8],"acid":[9],"plus":[10],"quetiapine":[11,108],"is":[12,92,109],"recommended":[13],"as":[14],"one":[15],"of":[16,22,55,60,105],"the":[17,61,66,69,89,125],"first-line":[18],"approaches":[19],"to":[20,73],"treatment":[21,48],"manic":[23],"or":[24],"mixed":[25],"episodes":[26],"in":[27,113,124],"patients":[28],"bipolar":[30,114],"disorder.":[31],"CASE":[32],"SUMMARY:":[33],"A":[34],"66-year-old":[35],"patient":[36],"this":[38,116],"psychiatric":[39],"disease":[40],"developed":[41],"parkinsonism":[42],"and":[43,107],"cognitive":[44],"decline":[45],"during":[46],"concomitant":[47,103],"both":[50],"drugs.":[51],"The":[52],"rapid":[53],"onset":[54],"symptoms":[56],"soon":[57],"after":[58],"use":[59,104],"combination":[62],"suggested":[63],"an":[64],"interaction/using":[65],"Karch-Lasagna":[67],"criteria,":[68],"interaction":[70,87,118],"was":[71],"judged":[72],"be":[74,120],"definite.":[75],"NEW":[78],"CONCLUSION:":[80],"Their":[81],"evidence":[82],"on":[83],"a":[84],"pharmacokinetic":[85],"drug":[86],"between":[88],"two":[90],"drugs":[91],"conflicting":[93],"but":[94],"possible":[95],"underlying":[96],"mechanisms":[97],"proposed":[98],"include":[99],"CYP3A4":[100],"inhibition.":[101],"As":[102],"valproate":[106],"now":[110],"quite":[111],"frequent":[112],"disorder,":[115],"potential":[117],"should":[119],"closely":[121],"monitored,":[122],"especially":[123],"elderly.":[126]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}